If you have recurrent or platinum-resistant ovarian cancer, your doctor may recommend folate receptor alpha (FRα) testing. If you test positive for elevated levels of FRα (expressed on 75 percent or ...
New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential ...
Figure 1: Panel of various pediatric tumors comparing H&E staining, FRα, and FRβ protein expression within the tumor. None of these tumors demonstrate FRα expression; however all of the tumors ...
Results of a study led by researchers at Roswell Park Comprehensive Cancer Center show that combining two types of immunotherapy—engineered T cells that secrete bispecific T cell engagers (BiTEs) and ...
Practice-changing data in endometrial cancer support checkpoint inhibitor–chemotherapy combinations, extending ...
A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for mirvetuximab soravtansine (an antibody-drug conjugate therapy), emphasizing ...
A panelist discusses how antibody-drug conjugates like mirvetuximab should be sequenced in platinum-resistant ovarian cancer, recommending it as first-line therapy for folate receptor alpha–high ...
Treating ovarian cancer remains a race against time. In Italy, eight out of ten women receive a late diagnosis, often when the disease is already at an advanced stage. To provide concrete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results